- Home
- ODD vs BLTE Comparison
ODD vs BLTE Comparison
Compare ODD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | BLTE |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ODD | BLTE |
|---|---|---|
| Price | $42.18 | $154.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $69.45 | ★ $149.00 |
| AVG Volume (30 Days) | ★ 689.5K | 294.5K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $780,758,000.00 | N/A |
| Revenue This Year | $26.15 | N/A |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | $23.40 | ★ N/A |
| Revenue Growth | ★ 25.80 | N/A |
| 52 Week Low | $35.30 | $49.00 |
| 52 Week High | $79.18 | $162.00 |
Technical Indicators
Market Signals| Indicator | ODD | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 64.42 |
| Support Level | $41.36 | $153.00 |
| Resistance Level | $44.09 | $157.00 |
| Average True Range (ATR) | 1.63 | 6.41 |
| MACD | -0.02 | -1.13 |
| Stochastic Oscillator | 16.56 | 61.95 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.